Scynexis, Inc.NASDAQ: SCYX

SCYNEXIS to Participate in Upcoming Investor Conferences

· Issued by Scynexis, Inc. via GlobeNewswire

Summary by 6ix AI

SCYNEXIS, Inc., a clinical-stage biotechnology company developing therapies for severe and difficult-to-treat diseases, will take part in two investor conferences in New York City in September 2026.

Key details

  • At the 12th Cantor Global Healthcare Conference in New York City, SCYNEXIS will hold a fireside chat on Friday, September 11, 2026, at 9:45 a.m. ET.
  • At the H.C. Wainwright 28th Annual Global Investment Conference in New York City, SCYNEXIS will hold one-on-one investor meetings on September 14-16, 2026.
  • A live webcast of the Cantor fireside chat will be available, with a replay available for 90 days after the event.

6ix AI wrote this summary from the release below and checked it against the release.

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:

  • 12th Cantor Global Healthcare Conference in New York City
    Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET.

  • H.C. Wainwright 28th Annual Global Investment Conference in New York City
    1x1 investor meetings: September 14-16, 2026

A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS's proprietary antifungal platform "fungerps" includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
[email protected]

Scynexis, Inc. on 6ix

Story so far

Earlier from Scynexis

Later from Scynexis

All Scynexis news releases